|
KMID : 0370220090530050259
|
|
Yakhak Hoeji
2009 Volume.53 No. 5 p.259 ~ p.264
|
|
|
Effect of Naringin on the Bioavailability of Losartan in Rats
|
|
Lee Chong-Ki
Choi Jun-Shik
|
|
|
Abstract
|
|
|
|
The present study was to investigate the effect of naringin, a flavonoid, on the pharmacokinetics of losartan in rats. Pharmacokinetic parameters of losartan in rats were determined after an oral administration of losartan (9 mg/kg) in the presence or absence of naringin (0.5, 2.5 and 10 mg/kg). The pharmacokinetic parameters of losartan were significantly altered by the presence of naringin compared with the control group (given losartan alone). Presence of naringin significantly (p<0.05, 2.5 mg/kg; p<0.01, 10 mg/kg) increased the area under the plasma concentration뻯ime curve (AUC) of losartan by 43.7~63.0% and peak plasma concentration (Cmax) of losartan by 31.7~45.5%. Consequently, the absolute bioavailability (AB) of losartan in the presence of naringin was 43.8~62.9%, which was enhanced significantly (p<0.05, p<0.01) compared to that in the oral control group (22.4%). The relative bioavailability (R.B.) of losartan increased by 1.44-to 1.63-fold in the presence of naringin. However, there was no significant change in the peak plasma concentration (Tmax) and terminal half-life (t1/2) of losartan in the presence of naringin. In conclusion, the presence of naringin significantly enhanced the oral bioavailability of losartan, implying that presence of naringin might be mainly effective to inhibit the cytochrome P450 (CYP)3A-mediated metabolism, resulting in reducing gastrointestinal and hepatic first-pass metabilism and Pglycoprotein (P-gp)-mediated efflux of losartan in small intestine. Concurrent use of naringin or naringin-containing dietary supplement with losartan should require close monitoring for potential drug interactions.
|
|
|
KEYWORD
|
|
|
losartan, bioavailability, naringin, pharmacokinetics, CYP3A4, p-gp, rat
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|